Back

A modified porous silicon microparticle promotes mucosal delivery of SARS-CoV-2 antigen and induction of potent and durable systemic and mucosal T helper 1 skewed protective immunity

Adam, A.; Shi, Q.; Wang, B.; Zou, J.; Mai, J.; Osman, S. R.; Wu, W.; Xie, X.; Aguilar, P. V.; Bao, X.; Shi, P.-Y.; Shen, H.; Wang, T.

2021-11-24 immunology
10.1101/2021.11.22.469576 bioRxiv
Show abstract

Development of optimal SARS-CoV-2 vaccines to induce potent, long-lasting immunity and provide cross-reactive protection against emerging variants remains a high priority. Here, we report that a modified porous silicon microparticle (mPSM)-adjuvanted SARS-CoV-2 receptor-binding domain (RBD) vaccine activated dendritic cells and generated more potent and durable SARS-CoV-2-specific systemic humoral and type 1 helper T (Th) cell-mediated immune responses than alum-formulated RBD following parenteral vaccination, and protected mice from SARS-CoV-2 and Beta variant infection. mPSM facilitated the uptake of SARS-CoV-2 RBD antigens by nasal and airway epithelial cells. Parenteral and intranasal prime and boost vaccinations with mPSM-RBD elicited potent systemic and lung resident memory T and B cells and SARS-CoV-2 specific IgA responses, and markedly diminished viral loads and inflammation in the lung following SARS-CoV-2 Delta variant infection. Our results suggest that mPSM can serve as potent adjuvant for SARS-CoV-2 subunit vaccine which is effective for systemic and mucosal vaccination.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Nature Communications
○ 5641 papers in training set
Top 17%
10.9%
Similar papers in this journal
2
npj Vaccines
○ 67 papers in training set
Top 0.1%
7.8%
Similar papers in this journal
3
Frontiers in Immunology
○ 638 papers in training set
Top 2%
7.8%
Similar papers in this journal
4
eLife
● 5828 papers in training set
Top 25%
5.1%
Similar papers in this journal
5
Molecular Therapy
○ 81 papers in training set
Top 0.3%
4.8%
Similar papers in this journal
6
Vaccine
○ 203 papers in training set
Top 0.7%
4.3%
7
Cell Reports
○ 1498 papers in training set
Top 10%
4.0%
8
Vaccines
○ 198 papers in training set
Top 1%
3.2%
9
Science Advances
● 1243 papers in training set
Top 11%
3.2%
50% of probability mass above
10
iScience
○ 1154 papers in training set
Top 7%
3.2%
11
mBio
● 833 papers in training set
Top 6%
2.6%
12
Journal for ImmunoTherapy of Cancer
● 75 papers in training set
Top 0.9%
2.4%
13
PLOS Pathogens
● 820 papers in training set
Top 5%
2.4%
14
Cell Discovery
○ 57 papers in training set
Top 0.4%
1.9%
15
eBioMedicine
○ 183 papers in training set
Top 3%
1.7%
16
Mucosal Immunology
○ 47 papers in training set
Top 0.6%
1.7%
17
Scientific Reports
○ 3612 papers in training set
Top 55%
1.7%
18
Science Immunology
● 88 papers in training set
Top 2%
1.3%
19
Microbiology Spectrum
● 469 papers in training set
Top 9%
1.1%
20
Emerging Microbes & Infections
○ 74 papers in training set
Top 0.9%
1.1%
21
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 35%
1.1%
22
The Journal of Immunology
◐ 166 papers in training set
Top 2%
1.1%
23
Science Translational Medicine
● 127 papers in training set
Top 2%
1.1%
24
JCI Insight
● 277 papers in training set
Top 6%
1.1%
25
Cellular & Molecular Immunology
○ 14 papers in training set
Top 0.1%
1.1%
26
Cell Reports Medicine
○ 153 papers in training set
Top 4%
1.1%
27
Biomaterials
○ 84 papers in training set
Top 1%
1.0%
28
Med
○ 39 papers in training set
Top 0.6%
1.0%
29
Cell Research
○ 51 papers in training set
Top 1%
0.8%
30
Allergy
○ 25 papers in training set
Top 0.4%
0.8%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.